22157.jpg
Global $4.54 Bn Induced Pluripotent Stem Cell (iPSC) Markets, 2021-2025 & 2030
September 14, 2021 05:53 ET | Research and Markets
Dublin, Sept. 14, 2021 (GLOBE NEWSWIRE) -- The "Induced Pluripotent Stem Cell (iPSC) Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change" report has been added to...
22157.jpg
The Worldwide Stem Cell Manufacturing Industry is Expected to Reach $18 Billion by 2026 at a CAGR of 9.4% from 2021
May 31, 2021 07:03 ET | Research and Markets
Dublin, May 31, 2021 (GLOBE NEWSWIRE) -- The "Global Stem Cell Manufacturing Market by Product (Consumables, Instrument, HSCs, MSCs, iPSCs, ESCs), Application (Research, Clinical (Autologous,...
22157.jpg
Global Organoids and Spheroids Market (2021 to 2028) - Share, Size, Trends & Industry Analysis Report
February 24, 2021 05:33 ET | Research and Markets
Dublin, Feb. 24, 2021 (GLOBE NEWSWIRE) -- The "Organoids and Spheroids Market Share, Size, Trends, Industry Analysis Report, By Type; By Application; By End-Use; By Regions; Segment Forecast,...
22157.jpg
Global Mesenchymal Stem Cells (MSC) Market Strategic Report 2021: Profiles & Activities of the Leading 98 MSC Companies
February 11, 2021 05:23 ET | Research and Markets
Dublin, Feb. 11, 2021 (GLOBE NEWSWIRE) -- The "Mesenchymal Stem Cells - Advances and Applications, 2021" report has been added to ResearchAndMarkets.com's offering. Mesenchymal stem cells (MSCs)...
Fate Therapeutics.jpg
Fate Therapeutics Presents Off-the-Shelf CAR T and NK Cell Cancer Immunotherapy Pipeline at ASH Annual Meeting
December 04, 2018 09:11 ET | Fate Therapeutics, Inc.
SAN DIEGO, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics.jpg
Fate Therapeutics Secures Exclusive Option to Novel Humanized anti-BCMA CAR Constructs for Development of iPSC-derived Cell Products
December 03, 2018 16:01 ET | Fate Therapeutics, Inc.
SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
TMlogo.jpg
Q Therapeutics Announces Joint Venture With REPROCELL
April 23, 2018 05:00 ET | Q Therapeutics, Inc.
PARTNERSHIP WILL DEVELOP IPSC-DERIVED PRODUCTS TO TREAT CENTRAL NERVOUS SYSTEM DISEASES INVOLVING DEMYELINATION AND DEGENERATIONSALT LAKE CITY and YOKOHAMA, Japan, April 23, 2018 (GLOBE NEWSWIRE) --...
Coriell Institute for Medical Research Logo
Coriell Institute Opens World's Largest Public Stem Cell Collection
September 01, 2015 09:37 ET | Coriell Institute for Medical Research
CAMDEN, N.J., Sept. 1, 2015 (GLOBE NEWSWIRE) -- Coriell Institute today announced the availability of the world's largest human pluripotent stem cell (hPSC) bank, which will enable disease research...
Patients' Own Skin Cells Are Transformed Into Heart Cells to Create "Disease in a Dish"
January 27, 2013 13:13 ET | Sanford-Burnham Medical Research Institute
LA JOLLA, Calif., Jan. 27, 2013 (GLOBE NEWSWIRE) -- Most patients with an inherited heart condition known as arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) don't know they have a...